YIH
RAPP

Y-Intercept (HK)’s Rapport Therapeutics RAPP Stock Holding History

Y-Intercept (HK)’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$800K Sell
19,189
-16,636
-46% -$611K 0.02% 1129
2026
Q1 		$1.12M Buy
+35,825
New +$1.01M 0.02% 985

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Y-Intercept (HK)'s RAPP Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Rapport Therapeutics (RAPP) stake by 46% in Q2 2026, selling an estimated $611K and leaving 19,189 shares worth $800K. The position accounts for 0.02% of the portfolio, ranked #1129.

Y-Intercept (HK) first reported a position in RAPP in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.12M in Q1 2026. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Y-Intercept (HK) held 19,189 shares of Rapport Therapeutics worth $800K as of Q2 2026.
  • Y-Intercept (HK) sold 16,636 Rapport Therapeutics shares in Q2 2026, an estimated $611K.
  • Rapport Therapeutics made up 0.02% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1129 holding.
  • Y-Intercept (HK) first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Y-Intercept (HK)'s Rapport Therapeutics position peaked at $1.12M in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.